TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32211953

Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation (MS) using letrozole/antagonist protocol
Number of subjects: 191

Group type: COMPARATOR
Intervention: Conventional controlled ovarian stimulation (COS) using high dose gonadotropin (Gn) and GnRH-a stop protocol
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation (MS)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Conventional controlled ovarian stimulation (COS)
Number of subjects: 191
Study: 35610015

Group type: EXPERIMENTAL
Intervention: Fuzheng Jiedu Xiaoji formula (FJXF) plus TACE
Number of subjects: 0

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FJXF plus TACE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 33045287

Group type: EXPERIMENTAL
Intervention: Mirabegron (25 mg, increased to 50 mg after 4 weeks)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 32912983

Group type: EXPERIMENTAL
Intervention: EQ-5D-Y
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CHU-9D
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EQ-5D-Y and CHU-9D
Number of subjects: 64
Study: 35953640

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 123

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 123
Study: 33185749

Group type: EXPERIMENTAL
Intervention: Impella 2.5/CP
Number of subjects: 423

Group type: COMPARATOR
Intervention: vaECMO
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Impella 2.5/CP (after adjustment)
Number of subjects: 423

Group type: COMPARATOR
Intervention: vaECMO (after adjustment)
Number of subjects: 423
Study: 35954850

Group type: EXPERIMENTAL
Intervention: Feeling-Word Checklist—28 (FWC‐28)
Number of subjects: 62
Study: 34274211

Group type: EXPERIMENTAL
Intervention: AIM2ACT intervention (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Self-guided attention control (n = 16)
Number of subjects: 33
Study: 33252962

Group type: EXPERIMENTAL
Intervention: LGBT stressors
Number of subjects: 121

Group type: COMPARATOR
Intervention: General stressors
Number of subjects: 121
Study: 35277398

Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g twice daily until delivery)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (2 g twice daily until delivery)
Number of subjects: 205
Study: 33813110

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800 mg on day 0 followed by 400 mg per day for 8 days)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 250
Study: 35584002

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community weight management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (matched for BMI, age, and sex)
Number of subjects: 0
Study: 34549408

Group type: EXPERIMENTAL
Intervention: Inhaling essential oil (Lavandula angustifolia 0.1 ml + citrus bergamia 0.1 ml) for 28 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control period (no essential oil) for 28 days
Number of subjects: 49
Study: 32600949

Group type: EXPERIMENTAL
Intervention: Nomogram developed using age at diagnosis, LND, and tumor size
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: High-risk group identified by nomogram
Number of subjects: 717
Study: 35596886

Group type: EXPERIMENTAL
Intervention: Piranha morcellator
Number of subjects: 210

Group type: COMPARATOR
Intervention: Versacut morcellator
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (Versacut morcellator)
Number of subjects: 210
Study: 34254651

Group type: EXPERIMENTAL
Intervention: Informative leaflet (LG)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 166
Study: 34653425

Group type: EXPERIMENTAL
Intervention: Plenvu (1L polyethylene glycol-based bowel preparation)
Number of subjects: 360
Study: 33862467

Group type: EXPERIMENTAL
Intervention: Food addiction explanation for eating behaviours
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Poor dietary and lifestyle choices explanation
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Higher BMI woman
Number of subjects: 757

Group type: COMPARATOR
Intervention: Lower BMI woman
Number of subjects: 757
Study: 34519561

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 40 mg, oral
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control procedure (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MAST (stress induction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 100
Study: 35869725

Group type: EXPERIMENTAL
Intervention: Baihe gujin decoction and Shengmai powder
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 100
Study: 34009348

Group type: EXPERIMENTAL
Intervention: AI-based wound assessment
Number of subjects: 199

Group type: COMPARATOR
Intervention: Human tracings
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: AI-based PGT measurements
Number of subjects: 199
Study: 33358942

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33915209

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Condition (CON)
Number of subjects: 20
Study: 35655534

Group type: EXPERIMENTAL
Intervention: Ropivacaine + dexmedetomidine (Group R1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ropivacaine + dexamethasone (Group R2)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ropivacaine (Group R)
Number of subjects: 97
Study: 33136231

Group type: EXPERIMENTAL
Intervention: Weekly nanoparticle albumin‐bound paclitaxel (nab‐PTX)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Weekly solvent‐based paclitaxel (Sb‐PTX)
Number of subjects: 303
Study: 34736731

Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Rivaroxaban plus antiplatelet therapy
Number of subjects: 2215
Study: 32062444

Group type: EXPERIMENTAL
Intervention: fampridine‐MR 10 mg bd
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 35986415

Group type: EXPERIMENTAL
Intervention: Sleep-Opt intervention (technology-assisted behavioral sleep intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy living attention control group
Number of subjects: 120
Study: 33478179

Group type: EXPERIMENTAL
Intervention: Personalized oral health education program in combination with routine dental care
Number of subjects: 579

Group type: COMPARATOR
Intervention: Routine dental care
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Personalized oral health education program
Number of subjects: 579
Study: 32270639

Group type: EXPERIMENTAL
Intervention: Combined treatment group (acupuncture at the 'thirteen ghost points' and kaixin powder)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chinese medication group (kaixin powder only)
Number of subjects: 60
Study: 35500910

Group type: EXPERIMENTAL
Intervention: Skiing (active skiing for at least 2 years)
Number of subjects: 68
Study: 33485159

Group type: EXPERIMENTAL
Intervention: Group Cooperative Class (GCC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional Class (CC)
Number of subjects: 99
Study: 35303014

Group type: EXPERIMENTAL
Intervention: IC+CCRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCRT+AC
Number of subjects: 0
Study: 33300039

Group type: EXPERIMENTAL
Intervention: Increased nut consumption (almonds, pistachios, walnuts, and other nuts)
Number of subjects: 5800

Group type: EXPERIMENTAL
Intervention: Tertiles of change in nut consumption
Number of subjects: 5800
Study: 35089159

Group type: EXPERIMENTAL
Intervention: Step-based goals (7000-10,000 steps/day)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Minute-based goals (50-200 minutes/week)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Transition probability for minute-based goals during graded goal phase
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Transition probability for step-based goals during graded goal phase
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Transition probability for minute-based goals during fixed goal phase
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Transition probability for step-based goals during fixed goal phase
Number of subjects: 212
Study: 34148803

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 32800909

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 146
Study: 92313688

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/24 h for 7 days (Group I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/12 h for 7 days (Group II)
Number of subjects: 15
Study: 36072904

Group type: EXPERIMENTAL
Intervention: Endoplasmic reticulum stress-related differentially expressed genes (DEGs) identified through machine learning methods.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis of potential biomarkers with immune cell infiltration.
Number of subjects: 0
Study: 33562015

Group type: EXPERIMENTAL
Intervention: Adherence to dietary targets (≥1 target achieved)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Adherence to dietary targets (≥2 targets achieved)
Number of subjects: 549
Study: 35966022

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation (0.1 g·kg‐1·day‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-supplemented control group (CON)
Number of subjects: 23
Study: 33131908

Group type: EXPERIMENTAL
Intervention: 320 mg/day anthocyanins
Number of subjects: 176
Study: 33105381

Group type: EXPERIMENTAL
Intervention: PAP one-repetition maximum warm-up (RMWU) after standard warm-up (SWU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAP eccentric flywheel warm-up (EWU) after standard warm-up (SWU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard warm-up (SWU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAP one-repetition maximum warm-up (RMWU)
Number of subjects: 0
Study: 35778960

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 46
Study: 34128908

Group type: EXPERIMENTAL
Intervention: Avocado-based Mediterranean diet with intake of 1/2 portion of Avocado per day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-fat high-complex carbohydrate diet
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Avocado-based Mediterranean diet
Number of subjects: 200
Study: 35192711

Group type: EXPERIMENTAL
Intervention: Polar Life Pod (PLP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Stationary tubs (TUB)
Number of subjects: 13
Study: 33593886

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-L1 inhibition in combination with chemotherapy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Durvalumab arm
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Exploratory analysis
Number of subjects: 162
Study: 32616559

Group type: EXPERIMENTAL
Intervention: RFM-visible
Number of subjects: 14

Group type: COMPARATOR
Intervention: RFM-masked
Number of subjects: 14
Study: 35180902

Group type: EXPERIMENTAL
Intervention: Eye relaxation system with far-infrared nanomaterials
Number of subjects: 120

Group type: COMPARATOR
Intervention: Visual-motor training
Number of subjects: 120
Study: 33900515

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (400 mg every day)
Number of subjects: 90
Study: 34874478

Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-LM3
Number of subjects: 40

Group type: COMPARATOR
Intervention: 68Ga-DOTATATE
Number of subjects: 40
Study: 32145279

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) exercise
Number of subjects: 117

Group type: COMPARATOR
Intervention: Simulated WBV (SIM) exercise
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 36127863

Group type: EXPERIMENTAL
Intervention: Prevention and Relationship Education's (PREP) Within My Reach (WMR) intervention
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 1129
Study: 32879450

Group type: EXPERIMENTAL
Intervention: Freshly prepared pasta meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chilled pasta meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chilled/reheated pasta meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 10
Study: 32824190

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted intervention (health education sessions, regular weight monitoring, feedback via smartphone application)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted intervention
Number of subjects: 573
Study: 36235575

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 2000 IU/day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 4000 IU/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 33359750

Group type: EXPERIMENTAL
Intervention: Yoga intervention (yogasanas with static loosening exercises for 50 min, 5 days a week for 3 months)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-Yoga group (simple physical exercises)
Number of subjects: 300
Study: 32348531

Group type: EXPERIMENTAL
Intervention: Intravitreal corticosteroid implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-VEGF agents
Number of subjects: 0
Study: 36011613

Group type: EXPERIMENTAL
Intervention: Elastic dynamic sling
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bobath sling
Number of subjects: 41
Study: 32344201

Group type: EXPERIMENTAL
Intervention: Continuous postoperative pericardial flushing (CPPF) method
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 170
Study: 33998541

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study: 32747361

Group type: EXPERIMENTAL
Intervention: Low-dose afabicin (i.v. 80 mg, followed by oral 120 mg, BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose afabicin (i.v. 160 mg, followed by oral 240 mg, BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin/linezolid (i.v. vancomycin 1 g or 15 mg/kg, followed by oral linezolid 600 mg, BID)
Number of subjects: 0
Study: 35941796

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0
Study: 34444281

Group type: EXPERIMENTAL
Intervention: Modified-active release therapy (mART)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (hot pack and educational briefing)
Number of subjects: 38
Study: 32356413

Group type: EXPERIMENTAL
Intervention: 12-hour fasting
Number of subjects: 160

Group type: COMPARATOR
Intervention: expedited oral feeding
Number of subjects: 160
Study: 34004046

Group type: EXPERIMENTAL
Intervention: Childhood obesity (1-SD increase in BMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic predisposition to childhood obesity
Number of subjects: 0
Study: 32473365

Group type: EXPERIMENTAL
Intervention: Mangifera indica leaf extract (MLE), 500 mg orally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mangifera indica leaf extract (MLE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 16
Study: 35643952

Group type: EXPERIMENTAL
Intervention: 10-day sequential treatment for H. pylori eradication
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 28
Study: 35049196

Group type: EXPERIMENTAL
Intervention: Viscera massage + lifestyle intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lifestyle intervention only
Number of subjects: 80
Study: 32133606

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 751

Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 751
Study: 35754258

Group type: EXPERIMENTAL
Intervention: FES + GT
Number of subjects: 34

Group type: COMPARATOR
Intervention: PLBO + GT
Number of subjects: 34
Study: 34107553

Group type: EXPERIMENTAL
Intervention: Cortical perforations of the recipient bed
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (intact cortex)
Number of subjects: 26
Study: 32646701

Group type: COMPARATOR
Intervention: White patients (reference group)
Number of subjects: 22638

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 22638

Group type: EXPERIMENTAL
Intervention: Asian patients
Number of subjects: 22638

Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 22638

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 22638
Study: 33226202

Group type: EXPERIMENTAL
Intervention: Protocol B (90 kVp, reduced radiation and standard CM dose)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Protocol C (90 kVp, standard radiation and reduced CM dose)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Protocols B and C
Number of subjects: 126

Group type: COMPARATOR
Intervention: Protocols A, B, and C
Number of subjects: 126
Study: 35309891

Group type: EXPERIMENTAL
Intervention: Active tsDCS and textured insoles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Active tsDCS and smooth insoles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sham tsDCS and textured insoles
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tsDCS and smooth insoles
Number of subjects: 23
Study: 33670235

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Assessment and Treatment including ACT (TEAM)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control (Treatment as Usual)
Number of subjects: 308
Study: 35934770

Group type: EXPERIMENTAL
Intervention: Switching arm (BI 695501 and adalimumab RP)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Continuous arm (adalimumab RP)
Number of subjects: 238
Study: 33354799

Group type: EXPERIMENTAL
Intervention: Total-etch/conventional composite (TC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Total-etch/bulk-fill composite (TB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-etch/conventional composite (SC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-etch/bulk-fill composite (SB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional composite
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bulk-fill composite
Number of subjects: 60
Study: 36432436

Group type: EXPERIMENTAL
Intervention: Nutraceutical group (MHD plus nutraceutical supplementation: Vitamin E, L-glutathione, silymarin, and hepato-active compounds)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (Mediterranean hypocaloric diet only)
Number of subjects: 68
Study: 34817396

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg intravenously)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32861773

Group type: EXPERIMENTAL
Intervention: STAND (Supporting Teens' Autonomy Daily)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 278
Study: 36438978

Group type: EXPERIMENTAL
Intervention: BIS-guided TIVA (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical practice (group S)
Number of subjects: 0
Study: 33309893

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine hydrochloride
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.9% NaCl solution (placebo)
Number of subjects: 84
Study: 36284288

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.2 mg IV)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 33765358

Group type: EXPERIMENTAL
Intervention: PF-06410293 (adalimumab-afzb) administered by prefilled syringe (PFS)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: PF-06410293 (adalimumab-afzb) administered by prefilled pen (PFP)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Both PFS and PFP
Number of subjects: 164
Study: 33823419

Group type: EXPERIMENTAL
Intervention: Group-based exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine activities
Number of subjects: 0
Study: 33075192

Group type: EXPERIMENTAL
Intervention: Individual physiotherapy for pelvic floor muscle training
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Group-based physiotherapy for pelvic floor muscle training
Number of subjects: 362
Study: 35965182

Group type: EXPERIMENTAL
Intervention: 2-mA anodal 20-minute tDCS over the left primary motor cortex, administered three consecutive sessions every month for five months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 23
Study: 33852738

Group type: EXPERIMENTAL
Intervention: Triphala toothwipes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo toothwipes
Number of subjects: 27
Study: 32044089

Group type: EXPERIMENTAL
Intervention: Dynamic culture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Static culture
Number of subjects: 100
Study: 33401946

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexcom G6 (rtCGM with predictive alerts)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dexcom G5 (rtCGM without predictive alerts)
Number of subjects: 75
Study: 32572439

Group type: EXPERIMENTAL
Intervention: AcceleDent® (vibratory device)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fixed appliance only
Number of subjects: 40